Ma­gen­ta's blood can­cer ADC faces two dose-lim­it­ing tox­i­c­i­ties, trig­ger­ing co­hort stop­page

Ma­gen­ta Ther­a­peu­tics has in­formed the FDA of two dose-lim­it­ing tox­i­c­i­ties in the high­est-dose group of its Phase I/II study. No more pa­tients will be dosed in that co­hort, the biotech said Tues­day.

The tox­i­c­i­ties were found in two of three pa­tients in that group, the com­pa­ny said. It has not iden­ti­fied any dose-lim­it­ing tox­i­c­i­ties in the first three co­horts of the tri­al, which in­clude 15 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER